Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04697576 · ClinicalTrials.gov registry record · Phase 1
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
A Phase 1 study of Metastatic Melanoma and Clinical Stage IV Cutaneous Melanoma AJCC v8, sponsored by Carlo Contreras.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT04697576 is a Phase 1 study of Metastatic Melanoma and Clinical Stage IV Cutaneous Melanoma AJCC v8 that is actively recruiting participants, run by Carlo Contreras. The registered enrollment target is 36 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04697576, a Phase 1 study of Metastatic Melanoma and Clinical Stage IV Cutaneous Melanoma AJCC v8, is actively recruiting participants, sponsored by Carlo Contreras.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease the size of the injected melanoma tumor, or the extent of the melanoma within the body.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- PROCEDURE Resection
- BIOLOGICAL Quadrivalent Inactivated Influenza Vaccine
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04697576
The ClinicalTrials.gov registry entry for NCT04697576 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (57% lower). The listed sponsor is Carlo Contreras, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Metastatic Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04697576 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT04697576 about?
NCT04697576 is a clinical study titled "Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma". This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intralesional) may decrease the...
What is the current status of trial NCT04697576?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-10-20. Estimated completion is 2027-12-31.
What conditions does trial NCT04697576 study?
This clinical trial studies the following conditions: Metastatic Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8.
What interventions are being tested in trial NCT04697576?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Resection (PROCEDURE), Quadrivalent Inactivated Influenza Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04697576?
This trial is sponsored by Carlo Contreras, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04697576 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
-
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.